TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05578339

Intervention type: DEVICE
Group type: OTHER
Intervention: Biometry
Description: Lens thickness, lens shape, anterior chamber depth, axial eye length and angle-to-angle will be used as explanatory variables (independent variables) and the size of the capsular bag will be used as main outcome parameter (dependent variable).
Study: NCT02109757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Software intervention and education
Description: Personal attenuation rating measurements will be taken before and after educating the patient using software program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education only
Study: NCT04421755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Produce delivery
Description: weekly home delivery of fresh fruits and vegetables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Produce delivery
Description: weekly home delivery of fresh fruits and vegetables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking classes
Description: weekly home delivery of fresh fruits and vegetables participants will be invited to participate in a Culinary Medicine cooking series. The OU Culinary Medicine cooking curriculum will involve a 3-part class series designed to build nutrition knowledge and cooking self-efficacy for preparing fresh F/Vs. Each session is \~2 hr. Core nutrition guidelines for blood pressure and blood sugar management will also be emphasized informed by an evidence-based Conceptual Model of Healthy Cooking. Classes will be conducted in small groups (\~16 participants) in an established teaching kitchen used by the culinary medicine program. Classes will be facilitated by a professional chef, a healthcare professional (dietitian, medical doctor, or trained medical student), and other support staff, including trained medical, dietetic, and public health students.
Study: NCT03292302

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELX-02
Description: Synthetic aminoglycoside
Study: NCT01047449

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No-touch SVG harvest vs conventional SVG harvest technique
Description: Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No-touch SVG harvest vs conventional SVG harvest technique
Description: Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-touch SVG harvest vs conventional SVG harvest technique
Description: Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)
Study: NCT02629653

Intervention type: DEVICE
Group type: OTHER
Intervention: endovascular cooling (Zoll system)
Description: The Zoll IVTM is an endovascular cooling system that consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585).
Study: NCT01047449

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No-touch SVG harvest vs conventional SVG harvest technique
Description: Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil supplementation vs placebo
Description: Fish oil supplementation \[1g tablets (55% fish oils - EPA:DHA 33%:22%)\] taken twice daily for 1 year post-op

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil supplementation vs placebo
Description: Fish oil supplementation \[1g tablets (55% fish oils - EPA:DHA 33%:22%)\] taken twice daily for 1 year post-op

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation vs placebo
Description: Fish oil supplementation \[1g tablets (55% fish oils - EPA:DHA 33%:22%)\] taken twice daily for 1 year post-op

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil supplementation vs placebo
Description: Fish oil supplementation \[1g tablets (55% fish oils - EPA:DHA 33%:22%)\] taken twice daily for 1 year post-op
Study: NCT01311219

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative Treatment
Description: A figure-of-8 brace will be applied to afflicted extremity in clinic. The patient will be instructed on proper application of the brace and asked to continue wearing the brace for 2 to 6 weeks, depending on the patient's level of comfort.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative Treatment-Plate Fixation
Description: Plate fixation of the clavicle fracture will be performed utilizing a 3.5-mm dynamic compression plate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative Treatment-Intramedullary Pinning
Description: Clavicle fracture will be repaired through intramedullary pinning using The Rockwood Clavicle Pin (DePuy Orthopaedics, Warsaw, IN).
Study: NCT01652690

Intervention type: BIOLOGICAL
Intervention: Denosumab
Description: This is an non-interventional study, therefore denosumab is administered as part of routine care and not for purposes of the study.
Study: NCT00855218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: 800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. \[twice daily\], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
Study: NCT02283398

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: without RIPC
Description: the cuff will be placed around the left arm without being inflated

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
Study: NCT03860636

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial Pattern on Ultrasound at ET
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial Pattern on Ultrasound at ET
Description: Ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial Pattern on Ultrasound at HCG
Description: Ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial Pattern on Ultrasound at TVOR
Description: Ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial Pattern on Ultrasound at co-ordination scan
Description: Ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial thickness at HCG
Description: Ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial thickness at TVOR
Description: Ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial thickness at ET
Description: Ultrasound scan
Study: NCT00579800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new software sequences, FIESTA and Vibrant-DE and IDEAL
Description: Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
Study: NCT01534143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic HSCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01302067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8mg
Description: Oral, 1 tablet per day, 12 weeks duration, 8mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4mg
Description: Oral, 1 tablet per day, 12 weeks duration, 4mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, 1 tablet per day, 12 weeks duration
Study: NCT01342289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -6, -5, -4, -3, and -2: 30 mg/m\^2/day IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -6, -5, -4, -3, and -2: 30 mg/m\^2/day IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -6, -5, -4, -3, and -2: 30 mg/m\^2/day IV.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Day -1: 200 centigray in one fraction.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Day -1: 200 centigray in one fraction.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Day -1: 200 centigray in one fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Days 5 to 35: 15 mg/kg PO three times per day; max daily dose 1 g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Days 5 to 35: 15 mg/kg PO three times per day; max daily dose 1 g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Days 5 to 35: 15 mg/kg PO three times per day; max daily dose 1 g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 60
Description: Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 90
Description: Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 90.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 120
Description: Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 120.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant
Description: Donor stem cells infused IV on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant
Description: Donor stem cells infused IV on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant
Description: Donor stem cells infused IV on Day 0.
Study: NCT02384187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin as premedication
Description: Patients will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
Study: NCT00475124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Monitoring of pacemaker
Description: Daily Home Monitoring data transmission from the implanted pacemaker to Home Monitoring service center.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Monitoring of pacemaker deactivated
Description: No Home Monitoring data transmission.
Study: NCT04959539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic transcanal tympanoplasty with attico-antrostomy
Description: Transcanal approach followed by atticotomy to remove the attic cholesteatoma sac

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic assisted canal wall up mastoidectomy
Description: traditional canal wall up mastoidectomy followed by endoscopic evaluation of the attic to exclude any remnant cholesteatoma
Study: NCT03581383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREP-C
Description: The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) is an interactive online tool that enables providers to provide a thorough assessment of a patient's psychosocial readiness to begin Hepatitis C treatment, and make a treatment plan to improve treatment readiness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREP-C
Description: The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) is an interactive online tool that enables providers to provide a thorough assessment of a patient's psychosocial readiness to begin Hepatitis C treatment, and make a treatment plan to improve treatment readiness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified ECHO
Description: The heart of the ECHO (Extension for Community Health Outcomes) model is its hub-and-spoke knowledge-sharing networks, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. The key modification is one patient visit in the specialty center resulting in co-management of patients with data sharing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Telemedicine Questionnaire
Description: The patient questionnaire includes questions about patient experiences with telemedicine visits with providers
Study: NCT04881383

Intervention type: DIAGNOSTIC_TEST
Intervention: OGTT and HbA1c
Description: An investigation form will be given to the patient to attend an approved private laboratory for blood pressure, weight, height, waist and hip circumferences, and a blood test on OGTT, HbA1c, complete blood count (CBC) and lipid profile within three months
Study: NCT04227184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium
Description: Drug to treat overactive bladder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium
Description: Drug to treat overactive bladder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo tablet containing no active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo tablet containing no active drug
Study: NCT02204332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Study: NCT04287595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy with orange essential oil
Study: NCT02393300

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
Study: NCT01662375

Intervention type: OTHER
Intervention: Surveillance and interview
Description: The interventional nature of the study is justified by the need for particular monitoring of patients in whom life support is withdrawn following the clinical team's decision. The questions posed to the patient's family and/or relatives, do not modify the care provided to the patient.
Study: NCT01056952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: O2stand
Description: Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: O2stand
Description: Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher \& Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. A facial mask composed of a transparent mask and a soft inflatable will be used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher \& Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. A facial mask composed of a transparent mask and a soft inflatable will be used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optiflow
Description: High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 \> 90%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optiflow
Description: High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 \> 90%
Study: NCT01528553

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8plate
Description: 12 mm or 16 mm plate. 24 mm or 36 mm screw

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staples (Richards, Smith & Nephew)
Description: Staples (3 on each side)
Study: NCT00957177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 300mg pregabalin orally 1 hour before operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03755076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual cuing
Description: The two perceptual cues are: (a) feedback about the time-lag between the two arms presented as a horizontal tilt of the common goal, and (b) different movement weighting coefficients to each arm to force greater movement contribution of the paretic arm in a bimanual context.
Study: NCT03819790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal insulin glargine and lixisenatide
Description: Soliqua (insulin glargine and lixisenatide): a titratable combination of long-acting basal insulin glargine and lixisenatide (Glucagon-like peptide-1 receptor agonist)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal insulin Basaglar/Lantus + gliclazide MR
Description: basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients can be administered with most tolerant dose of metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients can be administered with most tolerant dose of metformin
Study: NCT04488393

Intervention type: DEVICE
Intervention: MaterniT21 PLUS and GENOME Laboratory-Developed Tests
Description: Both the MaterniT21 PLUS and GENOME are intended for use as laboratory developed test that analyze ccfDNA extracted from a maternal blood sample utilizing Massively Parallel Sequencing (MPS) technology.
Study: NCT04207151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SNAPS intervention
Description: The intervention is multi-level yet, targets the weakest chains in the link of PrEP initiation at safety-net hospitals designed for scalability, sustainability, and implementability across a wide range of settings. It consists of Surveillance by STI testing, Navigation by unannounced patient navigators to the Sexual Health Clinic (SHC), Accelerated follow-up with providers with PrEP expertise, Point-of-care PrEP counseling and laboratory testing, and Seamless, consistent, longitudinal, comprehensive care (SNAPS). SNAPS will selectively target those care settings where PrEP prescribing is particularly rare or absent (eg, OB/GYN). Study team will utilize a quasi- experimental design to compare rates of PrEP uptake overall, PrEP initiation in disproportionately-impacted groups, and PrEP retention pre-versus post-initiation of SNAPS, controlling for secular trends.